drugset
drugset / Trial / NCT07347808

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

NCT07347808 ↗

Phase 1 Completed 16 enrolled Vincentage Pharma Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations of VCT220 in subjects with renal impairment.

Timeline

Start
2025-12-25
Primary completion
2026-01-18
Completion
2026-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject VCT220 Small molecule 40 mg Oral

Indications

obesity disorder